Compare Johnson & Johnson (JNJ) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs PepsiCo, Inc. — how do they compare? Johnson & Johnson trades at $249.37 (market cap $598.96B), while PepsiCo, Inc. trades at $134.91 (market cap $184.89B). The key difference: Johnson & Johnson is far larger — about 3.2× PepsiCo, Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| JNJ | PEP | |
|---|---|---|
Market Cap | $598.96B | $184.89B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $170.44 |
52-Week Low | $164.36 | $135.40 |
Enterprise Value | $631.90B | $227.39B |
Dividend Yield | 2.15% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
PepsiCo (PEP) trades at $134.73, down 1.74% on the day, with technical indicators showing a bearish trend. The company maintains strong profitability with a 10.78% net income margin and has beaten earnings estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analyst consensus remains a Buy with a $158.50 price target.
The outlook is mixed: strong cash flow and dividend yield near 4% support income investors, but near-term headwinds include pricing pressure and volatile technicals. Upside depends on North American sales recovery and margin expansion from cost controls, while risks involve competitive pressures and execution on pricing strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
